Evaluation of biopsy results during vertebral augmentation in patients with a known history of malignancy

To evaluate biopsy results during vertebral augmentation in vertebral compression fracture (VCF) patients with a known history of malignancy. An analysis of vertebral augmentation between 2012 and 2021 was performed retrospectively. Each level of VCF was biopsied, and all biopsies were sent for histopathological analyses. Imaging evaluation was performed in collaboration with an oncologist, a spine surgeon, and a radiologist. Patients were divided into two groups based on the preoperative imaging findings. Malignant VCF (MVCF) was presumed in group A, while osteoporotic VCF (OVCF) was presumed in group B. One hundred and fifty-six VCF patients with a known history of malignancy were included. Group A included 91 patients with preoperative imaging findings suspicious for MVCF. And 73 patients were finally diagnosed as MVCF, with biopsy results confirming imaging findings. The incidence of MVCF was 46.8%. Group B included 65 patients with imaging evidence of OVCF. And all biopsy results were negative for malignancy. The sensitivity of imaging evaluation for finding MVCF was 100%, and the specificity was 78.3%. A combination of X-ray, computed tomography (CT), and magnetic resonance imaging (MRI) is sufficient to distinguish MVCF from OVCF. Biopsy is not required to confirm the diagnosis during vertebral augmentation, if the imaging findings do not indicate MVCF in patients with a known history of malignancy. It is recommended to perform a biopsy in patients with preoperative imaging findings suspicious for MVCF. A combination of X-ray, CT, and MRI is sufficient to distinguish MVCF from OVCF. Biopsy is not required in patients without imaging signs of MVCF. Biopsy is recommended in patients with imaging findings suspicious for MVCF.